Form 4: Coya Therapeutics CEO Acquires 5,000 Shares in Open Market Purchase

Coya Therapeutics CEO, Arun Swaminathan, purchased 5,000 shares of common stock at a price of $7.3378 per share on November 11, 2024.

Summary

• Arun Swaminathan, the Chief Executive Officer of Coya Therapeutics, Inc., acquired 5,000 shares of the company's common stock.
• The transaction occurred on November 11, 2024.
• The shares were purchased at a price of $7.3378 per share.
• The purchase was a direct transaction.

Sentiment

Score: 6

Explanation: The document is a routine filing of an insider purchase. While the purchase is a positive sign, it is not a major event that would significantly impact sentiment.

Positives

• The CEO's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.
• The direct purchase indicates a personal investment by the CEO in the company's stock.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders, such as the CEO, make transactions in their company's stock. It is a common practice and provides transparency to the market.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is similar to other insider purchases reported by executives in comparable companies.
• The purchase of 5,000 shares is not unusual for a CEO and is within the typical range of insider transactions.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.
• The purchase demonstrates the CEO's confidence in the company, which could be reassuring to investors.

Key Dates

Keywords

Coya Therapeutics, Arun Swaminathan, insider trading, share purchase, common stock, CEO, SEC Form 4